Pre-Market NASDAQ Movers (REGN, LULU, CRUS, FMCN, ACHN, RIMM, AAPL, WBMD, ILMN, AFFY, BRCD, TEVA)

The top pre-market NASDAQ stock market gainers are: Regeneron Pharmaceuticals, Lululemon Athletica, Cirrus Logic, Focus Media Holding, Achillion Pharmaceuticals, Research In Motion and Apple. The top pre-market NASDAQ stock market losers are: WebMD Health, Illumina, Affymax, Brocade Communications Systems and Teva Pharmaceutical Industries.

Gainers

Regeneron Pharmaceuticals, Inc. (REGN) stock jumped 13.78 percent to $74.50 in pre-market trading. In a conference, Regeneron said Eylea had $24 milion to $25 million in sales to distributors in 2011 since the first sale of Nov. 21, 2011. For the full year 2012, the company expects Eylea sales of $140 million to $160 million.

Lululemon Athletica Inc. (LULU) stock climbed 11.43 percent to $59.55 in pre-market trading. The company said it raised its fourth quarter earnings guidance to range of $0.47 to $0.49 per share from previous forecast of $0.40 to $0.42 per share. The company also lifted its fourth quarter revenue outlook to range of $358 million to $363 million from previous estimate of $327 million to $332 million. Wall Street analysts predict profit of $0.42 per share on revenue of $334.47 million for the fourth quarter. Comparable-store sales for the fourth quarter are expected to reflect a low-to-mid twenties percentage increase on a constant-dollar basis, compared to previous forecast of a low to mid-teens sales growth.

Cirrus Logic Inc. (CRUS) stock soared 10.49 percent to $18.75 in pre-market trading. The company said it raised third quarter revenue guidance to $122 million from previous forecast range of $102 million to $108 million, while Wall Street predicts $105.1 million. The company expects gross margin for the third quarter to be about 54 percent. Revenue from audio products is estimated at $105 million and revenue from energy products is expected to be about $17 million. For the fourth quarter, the company anticipates revenue of about $105 million, while Wall Street predicts $98.49 million. Cirrus Logic said the strength in the last weeks of December indicated that demand remains robust following the holiday season.

Focus Media Holding Ltd. (FMCN) stock grew 6.84 percent to $19.99 in pre-market trading. The company said it is implementing a policy starting from 2012 to issue a recurring dividend with payments expected to equal about 25 percent of its annual adjusted earnings of the preceding fiscal year. The dividends will be paid out on a quarterly basis in the calendar year to shareholders of record as of March 31, June 30, Sept. 30 and Dec. 31 respectively. The dividend payments will commence in 2012 in respect of Focus Media's adjusted earnings for 2011. Starting from 2012, the company said it will also reserve up to an additional 30 percent of its annual adjusted earnings of the preceding fiscal year as funds that may be used, at the company's discretion, to increase the dividend payment or the size of the company's share repurchase program in effect at that time. The dividend and share repurchase fund policies will be reviewed by the board and management on an annual basis.

Achillion Pharmaceuticals, Inc. (ACHN) stock gained 5.45 percent to $10.25 in pre-market trading.

Research In Motion Ltd. (RIMM) stock increased 1.58 percent to $15.75 in pre-market trading.

Apple Inc. (AAPL) stock rose 1.02 percent to $426.05 in pre-market trading. BTIG Research has increased its profit estimates for Apple on strong iPhone sales in the fourth quarter.

Losers

WebMD Health Corp. (WBMD) stock plunged 24.31 percent to $27.80 in pre-market trading. The company said Wayne Gattinella has resigned from his position as Chief Executive Officer, President and as a member of its Board of Directors. Anthony Vuolo, currently serving as Chief Financial Officer and Chief Operating Officer, will serve as an interim CEO while the Board conducts a search to fill the position on a permanent basis. The responsibilities of the Chief Operating Officer position will be assumed by certain members of the Management Committee. Vuolo will continue to serve as Chief Financial Officer of WebMD. These management changes are effective immediately.

WebMD also said that, in late 2011, the independent directors of its Board of Directors commenced a process to consider strategic alternatives to enhance stockholder value. In connection with such process, the Board of Directors formed a Special Committee of independent directors, which was advised by independent financial and legal advisors. The Special Committee, with its advisers, had discussions with several potential acquirers of the company. The Special Committee has now terminated these discussions with potential acquirers and its process to review a potential sale of the company.

In addition, WebMD said it expects fourth quarter and full year 2011 results to be consistent with the financial guidance it provided on Nov. 2, 2011. Preliminarily, WebMD expects revenue and earnings to be between the low-end and midpoint of its financial guidance range. For the fiscal 2012, the company expects that revenue may be as much as 2 percent to 8 percent lower than 2011 revenue, with revenue declining more in the first half of the year and improving in the second half of the year. WebMD anticipates that its expenses will increase by as much as 5 percent to 8 percent in 2012 as compared to last year. WebMD expects that its 2012 Adjusted EBITDA and earnings to be significantly lower than 2011.

Illumina Inc. (ILMN) stock declined 5.72 percent to $30 in pre-market trading.

Affymax, Inc. (AFFY) stock decreased 1.31 percent to $6.80 in pre-market trading.

Brocade Communications Systems, Inc. (BRCD) stock declined 1.04 percent to $5.71 in pre-market trading. Brocade has received first-round bids from a handful of potential buyers as the company explores a sale, according to Reuters, citing sources familiar with the matter. Brocade, which has a market value of nearly $2.7 billion, hired Frank Quattrone's Qatalyst Partners in November to focus on a deal that could result in a leveraged buyout, the sources told Reuters.

Teva Pharmaceutical Industries Ltd. (TEVA) stock moved down 0.45 percent to $44.69 in pre-market trading.